- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT00992784
Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine in Elderly People
22 sierpnia 2018 zaktualizowane przez: GlaxoSmithKline
Observer-blind Safety and Immunogenicity Study of GlaxoSmithKline Biologicals' Influenza Vaccine GSK2186877A When Administered to Elderly Subjects
The purpose of the study is to evaluate the safety of GSK Biologicals' influenza vaccine.
Elderly subjects were randomized in the primary study (NCT00760617) and will now receive the same vaccine for the third time.
For this study the masking is "observer-blind" for elderly subjects and "open" for young adult subjects.
Przegląd badań
Status
Zakończony
Warunki
Interwencja / Leczenie
Typ studiów
Interwencyjne
Zapisy (Rzeczywisty)
370
Faza
- Faza 3
Kontakty i lokalizacje
Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.
Lokalizacje studiów
-
-
-
Rotterdam, Holandia, 3011 EN
- GSK Investigational Site
-
Rotterdam, Holandia, 3011 AA
- GSK Investigational Site
-
-
-
-
-
Berlin, Niemcy, 13347
- GSK Investigational Site
-
Berlin, Niemcy, 12627
- GSK Investigational Site
-
Berlin, Niemcy, 10435
- GSK Investigational Site
-
Hamburg, Niemcy, 22415
- GSK Investigational Site
-
Hamburg, Niemcy, 22335
- GSK Investigational Site
-
-
Baden-Wuerttemberg
-
Gueglingen, Baden-Wuerttemberg, Niemcy, 74363
- GSK Investigational Site
-
Mannheim, Baden-Wuerttemberg, Niemcy, 68161
- GSK Investigational Site
-
Rudersberg, Baden-Wuerttemberg, Niemcy, 73635
- GSK Investigational Site
-
Weinheim, Baden-Wuerttemberg, Niemcy, 69469
- GSK Investigational Site
-
-
Bayern
-
Augsburg, Bayern, Niemcy, 86150
- GSK Investigational Site
-
-
Nordrhein-Westfalen
-
Essen, Nordrhein-Westfalen, Niemcy, 45359
- GSK Investigational Site
-
Koeln, Nordrhein-Westfalen, Niemcy, 51069
- GSK Investigational Site
-
-
Rheinland-Pfalz
-
Mainz, Rheinland-Pfalz, Niemcy, 55131
- GSK Investigational Site
-
Rhaunen, Rheinland-Pfalz, Niemcy, 55624
- GSK Investigational Site
-
-
Sachsen
-
Dresden, Sachsen, Niemcy, 01067
- GSK Investigational Site
-
Freital, Sachsen, Niemcy, 01705
- GSK Investigational Site
-
Leipzig, Sachsen, Niemcy, 04103
- GSK Investigational Site
-
-
Sachsen-Anhalt
-
Magdeburg, Sachsen-Anhalt, Niemcy, 39112
- GSK Investigational Site
-
Wolmirstedt, Sachsen-Anhalt, Niemcy, 39326
- GSK Investigational Site
-
-
-
-
-
Eskilstuna, Szwecja, SE-631 88
- GSK Investigational Site
-
Karlskrona, Szwecja, SE-371 41
- GSK Investigational Site
-
Uppsala, Szwecja, SE-751 85
- GSK Investigational Site
-
-
Kryteria uczestnictwa
Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.
Kryteria kwalifikacji
Wiek uprawniający do nauki
19 lat i starsze (Dorosły, Starszy dorosły)
Akceptuje zdrowych ochotników
Tak
Płeć kwalifikująca się do nauki
Wszystko
Opis
Inclusion Criteria:
All subjects must satisfy ALL the following criteria at study entry:
- Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study. Specific attention should be given to the compliance potential of subjects with suspected drug or alcohol abuse.
- A male or female aged 19-43 years or >=66 years at the time of the vaccination and who participated in the study NCT00760617 and completed the 6-month follow-up.
- Written informed consent obtained from the subject.
- Free of an acute aggravation of the health status as established by clinical evaluation before entering into the study.
- Female subjects of non-childbearing potential may be enrolled in the study.
- Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or post-menopause.
- Female subjects of childbearing potential may be enrolled in the study if the subject:
- has practiced adequate contraception for 30 days prior to vaccination, and
- has a negative pregnancy test on the day of vaccination, and
- has agreed to continue adequate contraception for 2 months after the vaccination.
Exclusion Criteria:
The following criteria should be checked at the time of study entry. If ANY exclusion criterion applies, the subject must not be included in the study:
- Use of any investigational or non-registered product other than the study vaccine(s) within 30 days prior to vaccination, or planned use during the study period.
- Administration of other licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrolment in this study. Planned administration of an influenza vaccine other than the study vaccines or of a vaccine not foreseen in the study protocol during the entire study period.
- Vaccination against influenza since January 2009 with a seasonal influenza vaccine.
- Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the administration of the study vaccine.
- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
- History of hypersensivity to a previous dose of influenza vaccine.
- History of allergy or reactions likely to be exacerbated by any component of the vaccine(s).
- Acute clinically significant pulmonary, cardiovascular, hepatic, renal, neurological and psychiatric disorders, as determined by clinical evaluation or pre-existing laboratory screening tests.
Acute disease and/or fever at the time of enrolment.
- Fever is defined as temperature >=37.5°C on oral setting.
- Subjects with a minor illness without fever may be enrolled at the discretion of the investigator.
- Administration of immunoglobulins and/or any blood products within the three months preceding the administration of the study vaccine or planned administration during the study.
- Any medical conditions in which IM injections are contraindicated
- Pregnant or lactating female.
- Female planning to become pregnant or planning to discontinue contraceptive precautions.
Plan studiów
Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Zapobieganie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Poczwórny
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: New generation influenza vaccine GSK2186877A Group
Subjects aged ≥ 66 years receiving 1 dose of New generation influenza vaccine GSK2186877A
|
Single dose, intramuscular injection
|
|
Aktywny komparator: Fluarix elderly Group
Subjects aged ≥ 66 years receiving 1 dose of Fluarix vaccine
|
Single dose, intramuscular injection
|
|
Aktywny komparator: Fluarix young Group
Subjects aged 19-43 years receiving 1 dose of Fluarix vaccine
|
Single dose, intramuscular injection
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Czas trwania zamówionych ogólnych zdarzeń niepożądanych
Ramy czasowe: Dzień 0-6
|
Czas trwania zdefiniowano jako liczbę dni z dowolnym stopniem objawów ogólnych.
|
Dzień 0-6
|
|
Czas trwania zamówionych lokalnych zdarzeń niepożądanych
Ramy czasowe: Dzień 0-6
|
Czas trwania zdefiniowano jako liczbę dni z dowolnym stopniem objawów miejscowych.
|
Dzień 0-6
|
|
Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)
Ramy czasowe: Day 0-6
|
Grade 3 ecchymosis, redness and swelling was ≥ 100 millimeter (mm) and grade 3 pain was considerable pain at rest, that prevented normal everyday activities.
|
Day 0-6
|
|
Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs
Ramy czasowe: Day 0-6
|
Any fever was defined as oral temperature ≥ 38.0 degree centigrade (°C), grade 3 fever was oral temperature ≥ 39.0°C-≤ 40.0°C.
For other symptoms, any was defined as occurrence of any general symptom regardless of intensity grade, grade 3 was defined as general symptom that prevented normal activity and related was general symptom assessed by the investigator as causally related to the study vaccination.
|
Day 0-6
|
|
Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs
Ramy czasowe: Day 0-20
|
Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
Any was defined as occurrence of any unsolicited symptom regardless of intensity grade, grade 3 was unsolicited symptom that prevented normal activity and related was event assessed by the investigator as causally related to the study vaccination.
|
Day 0-20
|
|
Number of Subjects Reporting Any, Grade 3 and Related AEs With a Medically Attended Visit
Ramy czasowe: Day 0-179
|
For each solicited and unsolicited AE the subject experienced, the subject was asked if they had received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason.
Any was defined as occurrence of any symptom regardless of intensity grade, grade 3 was defined as symptom that prevented normal activity and related was general symptom assessed by the investigator as causally related to the study vaccination.
|
Day 0-179
|
|
Number of Subjects Reporting AEs of Specific Interest (AESI)
Ramy czasowe: Day 0-179
|
AESI for safety monitoring are a subset of AEs that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology.
Any was defined as occurrence of any symptom regardless of intensity grade, grade 3 was defined as symptom that prevented normal activity and related was general symptom assessed by the investigator as causally related to the study vaccination.
|
Day 0-179
|
|
Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) up to Day 180
Ramy czasowe: Up to Day 180
|
SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.
Any was defined as occurrence of any symptom regardless of intensity grade and related was event assessed by the investigator as causally related to the study vaccination.
|
Up to Day 180
|
|
Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) After Day 180
Ramy czasowe: After Day 180
|
SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.
Any was defined as occurrence of any symptom regardless of intensity grade and related was event assessed by the investigator as causally related to the study vaccination.
|
After Day 180
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Haemagglutination Inhibition (HI) Antibody Titers at Days 0 and 21
Ramy czasowe: Day 0 and Day 21
|
Antibody titers were expressed as Geometric mean titers (GMTs) against separate vaccine strains.
The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.
|
Day 0 and Day 21
|
|
HI Antibody Titers at Day 180
Ramy czasowe: Day 180
|
Antibody titers were expressed as GMTs against separate vaccine strains.
The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.
|
Day 180
|
|
The Number of Subjects Seropositive to HI Antibodies at Days 0 and 21
Ramy czasowe: Day 0 and Day 21
|
Seropositivity was defined as antibody titer greater than or equal to the cut-off value i.e ≥ 1:10.
|
Day 0 and Day 21
|
|
The Number of Subjects Seropositive to HI Antibodies at Day 180
Ramy czasowe: Day 180
|
Seropositivity was defined as antibody titer greater than or equal to the cut-off value i.e ≥ 1:10.
|
Day 180
|
|
The Number of Subjects Seroconverted to HI Antibodies at Day 21
Ramy czasowe: Day 21
|
A seroconverted subject was defined as a subject who had either a pre-vaccination titer < 1:10 and a post-vaccination titer ≥ 1:40 or a pre-vaccination titer ≥ 1:10 and at least a 4-fold increase in post-vaccination titer.
|
Day 21
|
|
The Number of Subjects Seroconverted to HI Antibodies at Day 180
Ramy czasowe: Day 180
|
A seroconverted subject was defined as a subject who had either a pre-vaccination titer < 1:10 and a post-vaccination titer ≥ 1:40 or a pre-vaccination titer ≥ 1:10 and at least a 4-fold increase in post-vaccination titer.
|
Day 180
|
|
HI Antibody Seroconversion Factors (SCF) at Day 21
Ramy czasowe: At Day 21
|
SCF was defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0.
|
At Day 21
|
|
HI Antibody SCF at Day 180
Ramy czasowe: At Day 180
|
SCF was defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0.
|
At Day 180
|
|
The Number of Subjects Seroprotected to HI Antibodies at Days 0 and 21
Ramy czasowe: At Day 0 and Day 21
|
A seroprotected subject was defined as a subject with a serum HI titer ≥ to 1:40 that usually is accepted as indicating protection.
|
At Day 0 and Day 21
|
|
The Number of Subjects Seroprotected to HI Antibodies at Day 180
Ramy czasowe: At Day 180
|
A seroprotected subject was defined as a subject with a serum HI titer ≥ 1:40 that usually is accepted as indicating protection.
|
At Day 180
|
|
The Geometric Mean (GM) Number of Influenza Specific Cluster of Differentiation 4 (CD4) T-cells Per Million CD4 T-cells for Each Vaccine Strains Expressing at Least Two Different Markers or Expressing Different Combinations of Markers at Days 0 and 21
Ramy czasowe: At Day 0 and Day 21
|
The markers assessed were Cluster of Differentiation 40 Ligand (CD40L), interleukin 2 (IL-2), tumour necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ) and vaccine strains tested included A/Brisbane, A/Uruguay and B/Brisbane antigens.
|
At Day 0 and Day 21
|
|
The GM Number of Influenza Specific Cluster of Differentiation 4 (CD4) T-cells Per Million CD4 T-cells for Each Vaccine Strain Expressing at Least Two Different Markers or Expressing Different Combinations of Markers at Day 180
Ramy czasowe: At Day 180
|
The markers assessed were CD40L, IL-2, TNF-α and IFN-γ and vaccine strains tested included A/Brisbane, A/Uruguay and B/Brisbane antigens.
|
At Day 180
|
Współpracownicy i badacze
Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.
Sponsor
Publikacje i pomocne linki
Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.
Daty zapisu na studia
Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.
Główne daty studiów
Rozpoczęcie studiów
15 października 2009
Zakończenie podstawowe (Rzeczywisty)
27 maja 2010
Ukończenie studiów (Rzeczywisty)
27 maja 2010
Daty rejestracji na studia
Pierwszy przesłany
1 października 2009
Pierwszy przesłany, który spełnia kryteria kontroli jakości
8 października 2009
Pierwszy wysłany (Oszacować)
9 października 2009
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
21 września 2018
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
22 sierpnia 2018
Ostatnia weryfikacja
1 maja 2018
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- 113094
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
TAK
Opis planu IPD
Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Badanie danych/dokumentów
-
Protokół badania
Identyfikator informacji: 113094Komentarze do informacji: For additional information about this study please refer to the GSK Clinical Study Register
-
Plan analizy statystycznej
Identyfikator informacji: 113094Komentarze do informacji: For additional information about this study please refer to the GSK Clinical Study Register
-
Indywidualny zestaw danych uczestnika
Identyfikator informacji: 113094Komentarze do informacji: For additional information about this study please refer to the GSK Clinical Study Register
-
Raport z badania klinicznego
Identyfikator informacji: 113094Komentarze do informacji: For additional information about this study please refer to the GSK Clinical Study Register
-
Specyfikacja zestawu danych
Identyfikator informacji: 113094Komentarze do informacji: For additional information about this study please refer to the GSK Clinical Study Register
-
Formularz świadomej zgody
Identyfikator informacji: 113094Komentarze do informacji: For additional information about this study please refer to the GSK Clinical Study Register
-
Formularz zgłoszenia przypadku z adnotacjami
Identyfikator informacji: 113094Komentarze do informacji: For additional information about this study please refer to the GSK Clinical Study Register
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .